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Purpose of the study
Treatment guidelines are mainly based on the evidence of
efficacy in clinical trials. However, treatment outcomes
may differ in observational cohort studies. We analysed
data from the STAR cohort, a German prospective, multi-
centre, observational study, which includes HIV+ patients
(pts) starting a lopinavir/ritonavir (LPV/r)-based regimen.
Our goal was to compare treatment outcomes in ART-
naïve pts compared to pre-treated, but PI-naïve pts.
Methods
48-week analysis: comparison of treatment responses to
LPV/r-based regimens in ART-naïve and PI-naïve pts using
on-treatment (OT), intent-to-treat (ITT) and Kaplan-
Meier (KM) analyses. Primary outcome parameters were
reaching a confirmed viral load (VL) <50 copies/ml, %
with VL <50 copies/ml, and time to reaching a confirmed
CD4 count >500/μl.
Summary of results
1,079 HIV+ pts (74% ART-naive) have been included in
the STAR cohort. Median age was 41 years (range: 20–76).
Currently, baseline values were available of 872 pts (76%
[662] ART-naïve). Median baseline VL and CD4 cell
counts differed significantly between ART-naïve and PI-
naïve pts (125,500 vs. 3,746 copies/ml, p < 0.001; 198 vs.
310/μl, p < 0.001).
At 48 weeks, VL was <50 copies/ml in 79% of ART-naive
and in 75% of PI-naive pts (OT) (ITT: 62% of ART-naive
and 60% of PI-naive pts). Median changes in CD4 cells
were +201/μl in ART-naïve and +135/μl in PI-naïve pts (p
< 0.001). In 60% of ART-naive pts, CD4 cells increased to
levels >350/μl and in 34% to levels >500/μl. In 73% of PI-
naive pts, CD4 cells increased to levels >350/μl and in
48% to levels >500/μl.
The probability of remaining of treatment was 78 vs. 77%
in ART-naïve vs. PI-naïve pts at 48 weeks (KM-analysis, p
= ns). The median time to confirmed VL <50 copies/ml
was 25 weeks in ART-naive and 13 weeks in PI-naïve pts;
time to >500 CD4 cells/μl was 73 weeks in ART-naïve and
48 weeks in PI-naive pts.
Conclusion
In this cohort study, virological outcomes of LPV/r-based
regimens were comparable in ART-naïve and in pre-
treated PI-naïve pts, reflecting good efficacy and durability
also in second- or third-line use of LPV/r. The probability
of remaining on treatment for 48 weeks was high in both
groups (78 and 77%); VL was <50 copies/ml in 79% of
ART-naive and in 75% of PI-naive pts (OT) (ITT: 62% and
60%). In 34% of ART-naive pts and in 48% of PI-naïve
pts, CD4 cells increased to levels >500/μl, demonstrating
an ongoing CD4 increase also in pre-treated PI-naïve pts.
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